[Federal Register Volume 77, Number 152 (Tuesday, August 7, 2012)]
[Notices]
[Page 47115]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-19194]



[[Page 47115]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; 
Cayman Chemical Company

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on June 1, 2012, Cayman Chemical 
Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the following basic classes of 
controlled substances:

------------------------------------------------------------------------
                       Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235).................................  I
Methcathinone (1237).............................  I
4-Methyl-N-methylcathinone (1248)................  I
N-Ethylamphetamine (1475)........................  I
N,N-Dimethylamphetamine (1480)...................  I
Aminorex (1585)..................................  I
4-Methylaminorex (cis isomer) (1590).............  I
Gamma Hydroxybutyric Acid (2010).................  I
1-Pentyl-3-(1-naphthoyl)indole (7118)............  I
1-Butyl-3-(1-naphthoyl)indole (7173).............  I
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl) indole  I
 (7200).
Alpha-ethyltryptamine (7249).....................  I
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-               I
 hydroxycyclohexyl]-phenol (7297).
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-                I
 hydroxycyclohexyl]-phenol (7298).
Lysergic acid diethylamide (7315)................  I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine       I
 (7348).
Marihuana (7360).................................  I
Tetrahydrocannabinols (7370).....................  I
Mescaline (7381).................................  I
3,4,5-Trimethoxyamphetamine (7390)...............  I
4-Bromo-2,5-dimethoxyamphetamine (7391)..........  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).......  I
4-Methyl-2,5-dimethoxyamphetamine (7395).........  I
2,5-Dimethoxyamphetamine (7396)..................  I
2,5-Dimethoxy-4-ethylamphetamine (7399)..........  I
3,4-Methylenedioxyamphetamine (7400).............  I
5-Methoxy-3,4-methylenedioxyamphetamine (7401)...  I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)...  I
3,4-Methylenedioxy-N-ethylamphetamine (7404).....  I
3,4-Methylenedioxymethamphetamine (7405).........  I
4-Methoxyamphetamine (7411)......................  I
5-Methoxy-N-N-dimethyltryptamine (7431)..........  I
Alpha-methyltryptamine (7432)....................  I
Bufotenine (7433)................................  I
Diethyltryptamine (7434).........................  I
Dimethyltryptamine (7435)........................  I
Psilocybin (7437)................................  I
Psilocyn (7438)..................................  I
5-Methoxy-N,N-diisopropyltryptamine (7439).......  I
N-Benzylpiperazine (7493)........................  I
3,4-Methylenedioxypyrovalerone (7535)............  I
3,4-Methylenedioxy-N-methylcathinone (7540)......  I
Amphetamine (1100)...............................  II
Methamphetamine (1105)...........................  II
Lisdexamfetamine (1205)..........................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of marihuana 
derivatives for research purposes. In reference to drug code 7360 
(Marihuana), the company plans to bulk manufacture cannabidiol. In 
reference to drug code 7370 (Tetrahydrocannabinols), the company will 
manufacture a synthetic THC. No other activity for this drug code is 
authorized for this registration.
    The company plans to manufacture the remaining listed controlled 
substances to supply these materials to the research and forensics 
community for drug testing and analysis.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR Sec.  1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than October 9, 2012

    Dated: July 30, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-19194 Filed 8-6-12; 8:45 am]
BILLING CODE 4410-09-P